News, Publications, and Press

ICML 2025 Presentation on KinDEL: DNA-Encoded Library Dataset for Kinase Inhibitors

BIO 2025: As pharma deploys AI across the value chain, data remains a challenge

insitro and UK’s INSIGHT at Moorfields Eye Hospital Announce Collaboration to Expand Research Efforts in Neurodegeneration and Related Conditions

The world’s largest bioresource of eye images offers window into human health and serves as basis of a new AI foundation model to boost drug discovery. SOUTH SAN FRANCISCO–insitro, a…

Pitfalls in performing genome-wide association studies on ratio traits

insitro makes headway on the harder road, discovering new ALS drug target

insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS

Distinctive machine learning platform combines proprietary disease models and screening techniques to reveal genetic insights that generate targets to transform ALS treatment SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–insitro, a machine learning-enabled…

Better drugs through AI? insitro CEO on what machine learning can teach Big Pharma

Extending the Coding-variant Allelic Series Test to Summary Statistics

On Nobel day for AI in drug discovery, Peninsula biotech, big drugmaker strike AI deal

AI biotech insitro partners with Lilly on metabolic disease drugs

Eli Lilly, insitro ink a new kind of AI drug development deal

insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases

Agreements will support insitro’s IND-enabling studies for first set of pipeline programs from its machine learning-powered platform New paradigm for biotech and pharma alliance reflects the convergence of multimodal data…

EmbedGEM: a framework to evaluate the utility of embeddings for genetic discovery

Channel vision transformers: an image is worth 1 x 16 x 16 words

Leading Clinical Research Innovator, Amy Abernethy, M.D., Ph.D., Joins insitro Board of Directors

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–insitro, a machine learning-powered drug discovery and development company, today announced that Amy Abernethy, M.D., Ph.D, has joined the company’s board of directors. Dr. Abernethy, who…

Compositional deep probabilistic models of DNA-encoded libraries

insitro, biotech AI’s quiet unicorn, unveils efforts in ALS, liver disease, and cancer at JPM

Machine learning across multiple imaging and biomarker modalities in the UK Biobank improves genetic discovery for liver fat accumulation

Machine learning enabled prediction of digital biomarkers from whole slide histopathology images

Deep learning analysis on images of iPSC-derived motor neurons carrying fALS-genetics reveals disease-relevant phenotypes

Modelling Cellular Perturbations with the Sparse Additive Mechanism Shift Variational Autoencoder

Channel Vision Transformers: An Image Is Worth 1 x 16 x 16 Words

A Pooled Cell Painting CRISPR Screening Platform Enables de novo Inference of Gene Function by Self-supervised Deep Learning

An allelic-series rare-variant association test for candidate-gene discovery

Contextual Vision Transformers for Robust Representation Learning

Learned phenotypic embeddings enable scalable imputation of high-content molecular data elucidating prognostic chromatin signatures

insitro on Forbes AI 50 list

DEL-Dock: Molecular Docking-Enabled Modeling of DNA-Encoded Libraries

Daphne Koller on Forbes 50 over 50 Entrepreneurs List

Machine Learning enabled Pooled Optical Screening in Human Lung Cancer Cells

insitro, Genomics England Collaborate on Machine Learning to Improve Database Searches

insitro and Genomics England Announce Partnership to Provide Multimodal Search Capabilities and Empower Data Exploration and Derivation of Novel Insights

SOUTH SAN FRANCISCO, Calif. & LONDON–(BUSINESS WIRE)–insitro, a machine learning-driven drug discovery and development company, and Genomics England today announced a collaboration to bring insitro’s machine learning powered embedding search…

insitro Raises $400 Million in Series C Financing

Proceeds will Support Continued Advancement of Founding Visionto Reshape Drug Discovery and Development of Transformative Medicines Paul McCracken, Senior Portfolio Manager, Thematic Investing, at CPP Investments, to Join Board of…

insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

insitro to Receive $50 Million in Upfront Cash with Total Potential Deal Value Over $2.1 Billion Collaboration to Advance Targets and Therapeutic Candidates SAN FRANCISCO–(BUSINESS WIRE)–insitro, a machine-learning driven drug…

Publications & Press

Posts

ICML 2025 Presentation on KinDEL: DNA-Encoded Library Dataset for Kinase Inhibitors

BIO 2025: As pharma deploys AI across the value chain, data remains a challenge

insitro and UK’s INSIGHT at Moorfields Eye Hospital Announce Collaboration to Expand Research Efforts in Neurodegeneration and Related Conditions

Pitfalls in performing genome-wide association studies on ratio traits

insitro makes headway on the harder road, discovering new ALS drug target

insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS

Better drugs through AI? insitro CEO on what machine learning can teach Big Pharma

Extending the Coding-variant Allelic Series Test to Summary Statistics

On Nobel day for AI in drug discovery, Peninsula biotech, big drugmaker strike AI deal

AI biotech insitro partners with Lilly on metabolic disease drugs

Eli Lilly, insitro ink a new kind of AI drug development deal

insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases

EmbedGEM: a framework to evaluate the utility of embeddings for genetic discovery

Channel vision transformers: an image is worth 1 x 16 x 16 words

Leading Clinical Research Innovator, Amy Abernethy, M.D., Ph.D., Joins insitro Board of Directors

Compositional deep probabilistic models of DNA-encoded libraries

insitro, biotech AI’s quiet unicorn, unveils efforts in ALS, liver disease, and cancer at JPM

Machine learning across multiple imaging and biomarker modalities in the UK Biobank improves genetic discovery for liver fat accumulation

Machine learning enabled prediction of digital biomarkers from whole slide histopathology images

Deep learning analysis on images of iPSC-derived motor neurons carrying fALS-genetics reveals disease-relevant phenotypes

Modelling Cellular Perturbations with the Sparse Additive Mechanism Shift Variational Autoencoder

Channel Vision Transformers: An Image Is Worth 1 x 16 x 16 Words

A Pooled Cell Painting CRISPR Screening Platform Enables de novo Inference of Gene Function by Self-supervised Deep Learning

An allelic-series rare-variant association test for candidate-gene discovery

Contextual Vision Transformers for Robust Representation Learning

Learned phenotypic embeddings enable scalable imputation of high-content molecular data elucidating prognostic chromatin signatures

insitro on Forbes AI 50 list

DEL-Dock: Molecular Docking-Enabled Modeling of DNA-Encoded Libraries

Daphne Koller on Forbes 50 over 50 Entrepreneurs List

Machine Learning enabled Pooled Optical Screening in Human Lung Cancer Cells

insitro, Genomics England Collaborate on Machine Learning to Improve Database Searches

insitro and Genomics England Announce Partnership to Provide Multimodal Search Capabilities and Empower Data Exploration and Derivation of Novel Insights

insitro Raises $400 Million in Series C Financing

insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Coursera Cofounder Daphne Koller Melds AI And Biology In Drug Startup insitro

An audience with Daphne Koller

The start-up striving to accelerate drug discovery

In a test for AI, a buzzy machine learning startup inks drug discovery deal with Gilead